Abstract：ObjectiveTo explore clinical effect of Trastuzumab combined with Gemcitabine or Capecitabine in the firstline treatment of HER-2 positive advanced breast cancer.Methods65 cases clinical data of HER-2 positive advanced breast cancer patients in our hospital from August 2012 to August 2016 were analyzed,which waere divided into the Herceptin combined with GEM group(30 cases)and the Herceptin combined with capecitabine group(35 cases)by different treatment method.The clinical efficacy and adverse reactions were observed in the two groups.ResultsThere was no significant difference between the two groups in the total remission rate of different metastatic sites (P＞0.05).There was no significant difference between the two groups in the incidence rate of adverse reactions,such as alopecia, leukopenia,thrombocytopenia,lower hemoglobin,gastrointestinal reaction,liver dysfunction,renal dysfunction,hand and foot syndrome and diarrhea (P＞0.05).ConclusionThe remission rate of Trastuzumab combined with Gemcitabine or Capecitabine in the first-line treatment of HER-2 positive advanced breast cancer is higher,adverse reactions can be tolerated,it is worthy of clinical promotion and application.
何江涛;王伟. 曲妥珠单抗联合吉西他滨或卡培他滨一线治疗HER-2阳性晚期乳腺癌的临床研究[J]. 中国当代医药, 2017, 24(13): 97-99.
HE Jiang-tao;WANG Wei. Clinicalresearch ofTrastuzumab combined with Gemcitabineor Capecitabine in the first-line treatment of HER-2 positive advanced breast cancer. 中国当代医药, 2017, 24(13): 97-99.
Huang H，Jiang Z，Wang T，et al.Single-agentcapecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer[J].Anti Cancer Drugs，2012，23（7）：718-723.
Karachaliou N，Ziras N，Syrigos K，et al.A muhicenter phase Ⅱ trial of docetaxel and capecitabine as salvage treatment in anthracy cline and taxane pretreated patients with metastatic breast cancer[J].Cancer Chemother Pharmacol，2012，70（1）：169-176.
Martin M，Makhson A，Gligorov J，et al.PhaseⅡ study of bevaci-zumab in combination with trastuzumab and capecitabine as first line treatment for HER-2-positive locally recurrent or metastatic breast cancer[J].Oncologist，2012，17 （4）：469-475.
Tan WW，Allred JB，Salim M，et al.PhaseⅡ interventional study（N0337）ofcapecitabineincombinationwithvinorelbine and tras tuzumab for first-or second-line treatment of HER2-positivemetastaticbreastcancer：anorthcentralcancertreatment group trial[J].Clin Breast Cancer，2012，12（2）：81-86.
Kamal AH，Camacho F，Anderson R，et al.Similarsurvival with single agent capecitabine or taxane in first-linetherapy for metastatic breast cancer[J].Breast Cancer Res Treat，2012，134（1）：371-378.
Stockler MR，Harvey VJ，Francis PA，et al.Capecitabine versus classical cyclophosphamide，methotrexate，and fluorouracil as first line chemotherapy for advanced breast cancer[J].J Clin Oncol，2011，29（34）：4498-4504.
Huang H，Jiang Z，Wang T，et al.Single-agent capecitabine main-tenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer[J].Anti-cancer Drugs，2012，23（7）：718-723.
京公网安备 11010502046607号